Yixintang Pharmaceutical Group Co., Ltd. (SHE:002727)

SHE:002727 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Operating Revenue	16,873	17,462	16,877	17,124	14,275	12,401
Other Revenue	538.72	538.72	503.73	307.42	312.21	255.01
Revenue	17,412	18,000	17,380	17,432	14,587	12,656
Revenue Growth (YoY)	-4.10%	3.57%	-0.29%	19.50%	15.26%	20.78%
Cost of Revenue	11,930	12,428	11,798	11,486	9,320	8,211
Gross Profit	5,482	5,573	5,582	5,946	5,267	4,446
Selling, General & Admin	5,131	5,166	4,663	4,512	4,087	3,541
Research & Development	10.75	9.71	10.2	8.74	5.39	0.84
Other Operating Expenses	-10.66	7.67	32.62	17.17	-13.93	0.55
Operating Expenses	5,147	5,190	4,739	4,628	4,082	3,546
Operating Income	334.45	383.26	843.93	1,318	1,185	899.78
Interest Expense	-135.91	-146.04	-135.34	-93.72	-136.22	-24.54
Interest & Investment Income	24.31	47.04	86.48	7.49	53.52	58.39
Currency Exchange Gain (Loss)	-	-	-	0.23	-0.09	-0.34
Other Non Operating Income (Expenses)	17.19	-7.75	-93.76	1.48	-4.53	-2.42
EBT Excluding Unusual Items	240.05	276.51	701.32	1,233	1,098	930.86
Impairment of Goodwill	-26.77	-26.77	-11.65	-12.29	-10.97	-13.19
Gain (Loss) on Sale of Investments	1.99	-3.43	-8.36	-5.72	-5.77	-
Gain (Loss) on Sale of Assets	14.7	3.18	1.12	-13.83	-13.41	-0.02
Asset Writedown	11.99	-2.17	-2.93	-13.85	-2.71	-2.45
Other Unusual Items	-40	-40	23.07	47.48	31.29	41.7
Pretax Income	201.95	207.31	702.56	1,235	1,097	956.89
Income Tax Expense	118.37	97.02	142.15	222	179.32	167.73
Earnings From Continuing Operations	83.57	110.29	560.41	1,013	917.21	789.17
Minority Interest in Earnings	6.65	3.85	-10.97	-2.98	4.38	0.79
Net Income	90.23	114.14	549.44	1,010	921.58	789.96
Net Income to Common	90.23	114.14	549.44	1,010	921.58	789.96
Net Income Growth	-42.17%	-79.23%	-45.60%	9.59%	16.66%	30.81%
Shares Outstanding (Basic)	584	592	597	593	590	572
Shares Outstanding (Diluted)	584	592	597	595	592	573
Shares Change (YoY)	-2.25%	-0.76%	0.27%	0.50%	3.32%	0.88%
EPS (Basic)	0.15	0.19	0.92	1.70	1.56	1.38
EPS (Diluted)	0.15	0.19	0.92	1.70	1.56	1.38
EPS Growth	-40.84%	-79.07%	-45.75%	9.05%	12.91%	29.67%
Free Cash Flow	1,633	1,466	1,862	2,148	1,400	753.18
Free Cash Flow Per Share	2.79	2.48	3.12	3.61	2.36	1.31
Dividend Per Share	0.500	0.300	0.400	0.400	0.300	0.300
Dividend Growth	25.00%	-25.00%	-	33.33%	-	-
Gross Margin	31.48%	30.96%	32.12%	34.11%	36.11%	35.13%
Operating Margin	1.92%	2.13%	4.86%	7.56%	8.13%	7.11%
Profit Margin	0.52%	0.63%	3.16%	5.79%	6.32%	6.24%
Free Cash Flow Margin	9.38%	8.14%	10.71%	12.32%	9.60%	5.95%
EBITDA	432.6	492.77	968.59	1,432	1,283	979.56
EBITDA Margin	2.48%	2.74%	5.57%	8.22%	8.80%	7.74%
D&A For EBITDA	98.15	109.51	124.66	114.46	98.08	79.78
EBIT	334.45	383.26	843.93	1,318	1,185	899.78
EBIT Margin	1.92%	2.13%	4.86%	7.56%	8.13%	7.11%
Effective Tax Rate	58.62%	46.80%	20.23%	17.98%	16.35%	17.53%
Revenue as Reported	17,412	18,000	17,380	17,432	14,587	12,656
Advertising Expenses	-	62.9	49.55	49.28	42.16	23.93

Source: S&P Global Market Intelligence. Standard template. Financial Sources.